Kirk Ways

2.7k total citations · 1 hit paper
20 papers, 2.1k citations indexed

About

Kirk Ways is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Kirk Ways has authored 20 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Endocrinology, Diabetes and Metabolism, 9 papers in Molecular Biology and 8 papers in Surgery. Recurrent topics in Kirk Ways's work include Diabetes Treatment and Management (10 papers), Pancreatic function and diabetes (8 papers) and Diabetes Management and Research (5 papers). Kirk Ways is often cited by papers focused on Diabetes Treatment and Management (10 papers), Pancreatic function and diabetes (8 papers) and Diabetes Management and Research (5 papers). Kirk Ways collaborates with scholars based in United States, Belgium and Australia. Kirk Ways's co-authors include Gary Meininger, Mehul Desai, Keith Usiskin, Ngozi Erondu, Julio Rosenstock, Paul Nyirjesy, George Capuano, Chikako Takagi, Lois E. H. Smith and Fumi Mori and has published in prestigious journals such as Journal of Biological Chemistry, Blood and PLoS ONE.

In The Last Decade

Kirk Ways

20 papers receiving 2.0k citations

Hit Papers

Vascular Endothelial Growth Factor–Induced Retinal Permea... 1997 2026 2006 2016 1997 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Vascular Endothelial Growth Factor–Induced Retinal Permeability Is Mediated by Protein Kinase C In Vivo and Suppressed by an Orally Effective β-Isoform–Selective Inhibitor
    1997 515 citations Lloyd Paul Aiello, Allen C. Clermont et al. Diabetes profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kirk Ways United States 15 1.3k 815 805 347 208 20 2.1k
Pierre-Jean Guillausseau France 19 669 0.5× 284 0.3× 362 0.4× 232 0.7× 28 0.1× 49 1.3k
Boris Ivandic Germany 29 149 0.1× 678 0.8× 535 0.7× 70 0.2× 85 0.4× 54 2.1k
Max H. Stickland United Kingdom 25 605 0.5× 313 0.4× 210 0.3× 74 0.2× 121 0.6× 50 2.5k
Bieke F. Schrijvers Denmark 15 306 0.2× 499 0.6× 178 0.2× 60 0.2× 75 0.4× 18 1.5k
Xiaohong Yang United States 19 278 0.2× 401 0.5× 901 1.1× 54 0.2× 106 0.5× 49 1.7k
Wanda S. LeJeune United States 17 100 0.1× 380 0.5× 235 0.3× 127 0.4× 49 0.2× 21 1.4k
Monica Maria Pagliara Italy 16 436 0.3× 217 0.3× 126 0.2× 456 1.3× 65 0.3× 52 1.4k
Usha Panchapakesan Australia 22 681 0.5× 593 0.7× 379 0.5× 19 0.1× 138 0.7× 32 1.8k
Torsten Kirsch Germany 25 210 0.2× 759 0.9× 234 0.3× 25 0.1× 88 0.4× 41 1.9k

Countries citing papers authored by Kirk Ways

Since Specialization
Citations

This map shows the geographic impact of Kirk Ways's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kirk Ways with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kirk Ways more than expected).

Fields of papers citing papers by Kirk Ways

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kirk Ways. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kirk Ways. The network helps show where Kirk Ways may publish in the future.

Co-authorship network of co-authors of Kirk Ways

This figure shows the co-authorship network connecting the top 25 collaborators of Kirk Ways. A scholar is included among the top collaborators of Kirk Ways based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kirk Ways. Kirk Ways is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rosenthal, Norm, Gary Meininger, Kirk Ways, et al.. (2015). Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Annals of the New York Academy of Sciences. 1358(1). 28–43. 79 indexed citations
2.
Erondu, Ngozi, Mehul Desai, Kirk Ways, & Gary Meininger. (2015). Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care. 38(9). 1680–1686. 238 indexed citations
3.
Mamidi, Rao N. V. S., Sandra De Jonghe, Bianca Feyen, et al.. (2014). Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin. Chemico-Biological Interactions. 221. 109–118. 17 indexed citations
4.
5.
Nyirjesy, Paul, Jack D. Sobel, Albert Fung, et al.. (2014). Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion. 30(6). 1109–1119. 127 indexed citations
6.
Neal, Bruce, Vlado Perkovic, Dick de Zeeuw, et al.. (2014). Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes. Diabetes Care. 38(3). 403–411. 183 indexed citations
7.
Nyirjesy, Paul, Yue Zhao, Kirk Ways, & Keith Usiskin. (2012). Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Current Medical Research and Opinion. 28(7). 1173–1178. 119 indexed citations
8.
Liang, Yin, Kenji Arakawa, Kiichiro Ueta, et al.. (2012). Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models. PLoS ONE. 7(2). e30555–e30555. 200 indexed citations
9.
Devineni, Damayanthi, Linda Morrow, Marcus Hompesch, et al.. (2012). Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obesity and Metabolism. 14(6). 539–545. 192 indexed citations
10.
Nicolle, Lindsay E., George Capuano, Kirk Ways, & Keith Usiskin. (2012). Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Current Medical Research and Opinion. 28(7). 1167–1171. 67 indexed citations
11.
Garg, Satish K., Julio Rosenstock, & Kirk Ways. (2005). Optimized Basal-Bolus Insulin Regimens in Type 1 Diabetes: Insulin Glulisine Versus Regular Human Insulin in Combination with Basal Insulin Glargine. Endocrine Practice. 11(1). 11–17. 85 indexed citations
12.
Dailey, George, Julio Rosenstock, Robert G. Moses, & Kirk Ways. (2004). Insulin Glulisine Provides Improved Glycemic Control in Patients With Type 2 Diabetes. Diabetes Care. 27(10). 2363–2368. 113 indexed citations
13.
14.
Aiello, Lloyd Paul, Allen C. Clermont, Elia J. Duh, et al.. (1997). Vascular Endothelial Growth Factor–Induced Retinal Permeability Is Mediated by Protein Kinase C In Vivo and Suppressed by an Orally Effective β-Isoform–Selective Inhibitor. Diabetes. 46(9). 1473–1480. 515 indexed citations breakdown →
15.
DeVente, James, et al.. (1996). Phorbol ester stimulated Cip1 expression in p53-negative leukemic cells. Oncology Reports. 3(1). 213–7. 2 indexed citations
16.
Ways, Kirk, et al.. (1993). 2-Chloroadenosine prevents phorbol ester-induced depletion of protein kinase C in porcine coronary artery. American Journal of Physiology-Heart and Circulatory Physiology. 264(5). H1465–H1471. 8 indexed citations
17.
Standaert, Mary L., Héctor H. Hernández, James Watson, et al.. (1992). Effects of insulin on diacylglycerol/protein kinase-C signalling and glucose transport in rat skeletal muscles in vivo and in vitro.. Endocrinology. 130(6). 3345–3355. 34 indexed citations
18.
Farese, Robert V., Mary L. Standaert, Alan François, et al.. (1992). Effects of insulin and phorbol esters on subcellular distribution of protein kinase C isoforms in rat adipocytes. Biochemical Journal. 288(1). 319–323. 65 indexed citations
19.
Ways, Kirk, et al.. (1991). Effect of phorbol esters on cytosolic protein kinase C content and activity in the human monoblastoid U937 cell.. Journal of Biological Chemistry. 266(2). 1258–1264. 31 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pierre-Jean Guillausseau Breakdown of academic impact, for papers by Boris Ivandic Breakdown of academic impact, for papers by Max H. Stickland Breakdown of academic impact, for papers by Bieke F. Schrijvers Breakdown of academic impact, for papers by Xiaohong Yang Breakdown of academic impact, for papers by Wanda S. LeJeune Breakdown of academic impact, for papers by Monica Maria Pagliara Breakdown of academic impact, for papers by Usha Panchapakesan Breakdown of academic impact, for papers by Torsten Kirsch
Rankless by CCL
2026